This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Albendazole

Read time: 1 mins
Marketing start date: 18 Nov 2024

Summary of product characteristics


Effective Time

20221013

Version

4

Spl Product Data Elements

Albendazole Albendazole ALBENDAZOLE ALBENDAZOLE CELLULOSE, MICROCRYSTALLINE HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE POLYETHYLENE GLYCOL, UNSPECIFIED POVIDONE K30 SACCHARIN SODIUM SILICON DIOXIDE SODIUM LAURYL SULFATE SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN TALC TITANIUM DIOXIDE WHITE TO OFF WHITE ROUND 1021

Application Number

ANDA208979

Brand Name

Albendazole

Generic Name

Albendazole

Product Ndc

70771-1103

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1103-7 Albendazole Tablets USP, 200 mg 28 Tablets Rx only Albendazole tablets

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.